“CRS is a big problem” Dr @MyMKaiser, Consultant Haemato-Oncologist The Institute of Cancer Research & Royal Marsden Hospital discusses Cytokine Release Syndrome (CRS) and its impact on cancer immunotherapy administration. Treatment is limited to specialist cancer clinics due to

The @WHO has released first-ever global Guidance on GLP-1 Medicines for treating obesity as a chronic, relapsing disease. Obesity now affects 1+ billion people worldwide — and without major action, that number could double by 2030. Key takeaways from the guidance: ✅GLP-1

Our CEO Jeremy Skillington was quoted in @DDWJournal recent article highlighting the energetic and optimistic atmosphere at London Life Science Week, and the encouraging outlook for 2026. “The long-awaited corner has been turned! There’s a clear sense the industry is moving

Our team will be in San Francisco in January for J.P. Morgan Healthcare Week, one of the most influential global gatherings for pharma and biotech leaders. Get in touch to schedule a meeting to learn more about our high-value programmes targeting critical unmet medical needs,

Poolbeg Pharma is a clinical-stage biopharma company with high-value programmes, a proven leadership team, and with multiple near-term value inflection points, POLB is well positioned to drive significant value creation. Swipe through to explore: 🔹 Breakthrough programmes

Poolbeg Pharma was featured in a @ShoreCapital note following the grant of Poolbeg's European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza by the European Patent Office. 💪Strengthened IP protection 🧑‍🔬Advancing to Phase 2a study

Many congratulations to our esteemed NED and Scientific Advisory Board member , Professor Luke O’Neill, on being awarded an Honorary Doctorate by the Royal College of Surgeons 🎓 in Ireland at yesterday’s #RCSIConferring ceremony. This honour is a testament to Luke’s remarkable

Our CEO Jeremy Skillington, PhD, who is currently at London Life Sciences Week, discusses the European Patent Office has granted Poolbeg's European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza and highlights how this further

The European Patent Office has granted Poolbeg’s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. POLB 001 is a potent & selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the

Our Principal Scientist Liam Tremble will be back at this year's 67th @ASH_hematology ASH Annual Meeting & Exposition. 📍Orlando, Florida 🗓️ 6-9 December 2025 🏢 Orange County Convention Center This conference is the world's premier global hematology event and brings together

A reminder that our team will be attending this week's London Life Sciences Week! We invite you to connect with Poolbeg Pharma via the PartneringOne platform to arrange a meeting. This is an excellent opportunity to exchange insights, explore potential collaborations, and learn

The team have been busy with conference season in full swing. Our CEO Jeremy Skillington & Principal Scientist Liam Tremble caught up with @zakmir on @ShareTalkNews on their thoughts about the recent conferences & what's next on Poolbeg's radar. ☑️ESMO Conference key take aways

Our lead candidate, POLB 001, continues to make impressive progress as a potential breakthrough in preventing Cytokine Release Syndrome (CRS) — a dangerous inflammatory reaction seen with advanced cancer immunotherapies like CAR-T and bispecific antibodies. Check out our new

Video clips & a post-event update from CEO Jeremy Skillington at this weeks' EBD Group's BIO-Europe in Vienna! The team were delighted to join so many industry colleagues to explore the future of biotech and pharma. A big thank you to everyone who took the time to connect

Our CEO provides an overview on the clear plan to deliver shareholder returns through Poolbeg’s strategic & financial highlights. 🔹Our partnering focused model of cost-effective trials have been designed to produce high-quality human data and accelerate partnering discussions

Our team will be attending London Life Science Week, taking place from 16–21 November. London Life Sciences week brings together the global investor community and members of the world's dynamic life sciences sector to forge valuable partnerships, explore new opportunities, and

This @FT article titled "The race to launch a pill for weight loss" highlights that despite the success with injectable weight-loss drugs, pharma companies are continuing to invest heavily in orally delivered alternatives. 💊 Oral pills considered as the "holy grail of

A reminder that our team we will be attending EBD Group's BIO Europe in Vienna on 3-5 November. BIO Europe is a great opportunity to explore partnerships, exchange insights, and discuss the future of biotech and life sciences. To schedule a meeting with our CEO Jeremy

At Poolbeg pharma, we have a pipeline of high value programmes. Our Chief Executive Officer, Jeremy Skillington provides an overview of our key assets, POLB 001 & Oral Encapsulated GLP-1, including their near-term clinical value inflection points, making the well positioned for

Our CEO Jeremy Skillington and Executive Chair Cathal Friel spoke with Alan Healy from the @irishexaminer to discuss all things Poolbeg Pharma, including how we plan to drive innovation in support of cancer immunotherapy treatments and beyond. 💊 Our upcoming UK clinical trial

Our Principal Scientist Liam Tremble spoke with Nicole Raleigh, editor of @pharmaphorum at @myESMO, on Poolbeg Pharma’s mission to transform the cancer immunotherapy landscape with POLB 001. 🧑‍🔬 Upcoming Phase 2a clinical trial evaluating POLB 001’s safety and efficacy